Equity Mates: Buy or Sell – Cochlear, Telix, Life360, Pinnacle and more
I recently joined Adam Keily on Equity Mates for their Buy or Sell series.
We kicked off the episode by discussing the market volatility experienced this year, including insights into how the Trump administration has influenced global markets.
In this episode we delved into some companies that have caught our attention. Below is a summary of the stocks we discussed and the reasons we find them appealing.
Big Caps
Cochlear (ASX: COH) – Global leader in hearing implants, benefiting from underpenetrated markets, product innovation, and growing demand among seniors and emerging economies.
QBE Insurance Group (ASX: QBE) – Turnaround insurer with improved underwriting, rising bond yields, and undervalued shares despite strengthened profitability and disciplined risk exposure.
Telix Pharmaceuticals (ASX: TLX) – Fast-growing oncology company with a hit diagnostic product and strong pipeline, vertically integrated for global expansion and commercial success.
TechnologyOne (ASX: TNE) – Dominant enterprise software provider to governments, expanding internationally with high-margin SaaS model and consistent double-digit growth record.
Life360 (ASX: 360) – Location-based safety app with growing global users, high engagement, and monetisation tailwinds across ads, subscriptions, and emerging tracking technology.
Small Caps
Superloop (ASX: SLC) – Low-cost telco challenger gaining market share via efficient infrastructure, smart partnerships, and scalable, high-margin business model.
Bapcor (ASX: BAP) – Largest automotive parts distributor with turnaround potential, earnings upside, and structural tailwinds from ageing cars and population growth.
Pinnacle Investment Management (ASX: PNI) – Fast-growing asset manager leveraging boutique partnerships, benefiting from diversified income, private credit demand, and rising global investor appetite.
Ingenia Communities Group (ASX: INA) – Affordable housing and holiday park provider backed by demographic trends, solid execution, and exposure to rate cuts and domestic travel.
Imdex (ASX: IMD) – Mining tech innovator enabling efficient drilling decisions, well-positioned for exploration rebound amid high commodity prices and strong IP advantage.
AUB Group (ASX: AUB) – Insurance broker for SMEs with resilient earnings, offshore growth from UK acquisition, and upside from organic expansion.
Disclaimer:
The Australian Eagle Equities Fund, the Montgomery [Private] Fund, and The Montgomery Fund owns shares in Cochlear, QBE Insurance, Telix Pharmaceuticals, TechnologyOne, and Life360. The Montgomery Small Companies Fund own shares in Superloop, Bapcor, Pinnacle Investment Management, Ingenia Communities Group, Imdex, and AUB Group.
This article was prepared 19 June 2025 with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade Cochlear, QBE Insurance, Telix Pharmaceuticals, TechnologyOne, Life360, Superloop, Bapcor, Pinnacle Investment Management, Ingenia Communities Group, Imdex or AUB Group , you should seek financial advice.
Roger Montgomery is the Founder and Chairman of Montgomery Investment Management. Roger has over three decades of experience in funds management and related activities, including equities analysis, equity and derivatives strategy, trading and stockbroking. Prior to establishing Montgomery, Roger held positions at Ord Minnett Jardine Fleming, BT (Australia) Limited and Merrill Lynch.
He is also author of best-selling investment guide-book for the stock market, Value.able – how to value the best stocks and buy them for less than they are worth.
Roger appears regularly on television and radio, and in the press, including ABC radio and TV, The Australian and Ausbiz. View upcoming media appearances.
This post was contributed by a representative of Montgomery Investment Management Pty Limited (AFSL No. 354564). The principal purpose of this post is to provide factual information and not provide financial product advice. Additionally, the information provided is not intended to provide any recommendation or opinion about any financial product. Any commentary and statements of opinion however may contain general advice only that is prepared without taking into account your personal objectives, financial circumstances or needs. Because of this, before acting on any of the information provided, you should always consider its appropriateness in light of your personal objectives, financial circumstances and needs and should consider seeking independent advice from a financial advisor if necessary before making any decisions. This post specifically excludes personal advice.
